Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome

Title:Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome

Volume: 27 Issue: 35

Author(s): Rosaria V. Giglio, Anca P. Stoian, Angelo M. Patti*, Ali A. Rizvi, Vasily Sukhorukov, Marcello Ciaccio, Alexander Orekhov and Manfredi Rizzo

Affiliation:

• Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo,Italy

Keywords: Metabolic syndrome, inflammation, genetic, epigenetic, metabolic pathways, biomarkers, management.

Abstract:

Background: Metabolic syndrome is a clinical condition that deserves special attention because it puts the individual at high cardiovascular risk, especially heart attack and stroke. Considering precision medicine, it would be advisable to evaluate the individual cardio-metabolic risk by estimating the coexistence of risk factors (abdominal obesity, low level of High-Density Lipoprotein Cholesterol, High Triglycerides, and small dense Low-Density Lipoproteins sub-classes, hypertension, and elevated fasting glycemia), which could engrave on metabolism increasing cardiovascular mortality.

Objective: To identify genetic and epigenetic biomarkers may assist in the possibility of helping follow-up strategies and other measures of prevention and in metabolic risk.

Methods: We searched for studies that valued the combination between epigenetic biomarkers and all factors of cardio-metabolic risk.

Results: Numerous researches have investigated the molecular start of metabolic alterations, focusing on the epigenetic mark, as methylation of DNA, histone modifications and non.coding RNAs. It has been found that DNA methylation is the most searched epigenetic sign in the human genome concerning the control of gene expression.

Conclusion: For the screening, diagnosis, and prognosis of metabolic syndrome and the prescription of personalized medicine, the DNA methylation biomarkers specify for subjects have been recognized as an ensuring tool. While these results are promising, further investigations are needed to unravel the complicated synergic association of the genome, epigenome and the situations related to metabolic pathology.

Cite this article as:

Giglio V. Rosaria, Stoian P. Anca, Patti M. Angelo *, Rizvi A. Ali , Sukhorukov Vasily , Ciaccio Marcello, Orekhov Alexander and Rizzo Manfredi , Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome, Current Pharmaceutical Design 2021; 27 (35) . https://dx.doi.org/10.2174/1381612827666210412145915